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A B S T R A C T
Background
Respiratory support is a central component of themanagement of critically ill children. It can be delivered invasively via an endotracheal
tube or non-invasively via face mask, nasal mask, nasal cannula or oxygen hood/tent. Invasive ventilation can be damaging to the lungs,
and the tendency to use non-invasive forms is growing. However, non-invasive delivery is often poorly tolerated by children. High-
flow nasal cannula (HFNC) oxygen delivery is a relatively new therapy that shows the potential to reduce the need for intubation and
be better tolerated by children than other non-invasive forms of support. HFNC therapy differs from other non-invasive forms of
treatment in that it delivers heated, humidified and blended air/oxygen via nasal cannula at rates > 2 L/kg/min. This allows the user to
deliver high concentrations of oxygen and to potentially deliver continuous distending pressure; this treatment often is better tolerated
by the child.
Objectives
To determine whether HFNC therapy is more effective than other forms of non-invasive therapy in paediatric patients who require
respiratory support.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 4); MEDLINE via PubMed (January 1966
to April 2013); EMBASE (January 1980 to April 2013); CINAHL (1982 to April 2013); and LILACS (1982 to April 2013). Abstracts
from conference proceedings, theses and dissertations and bibliographical references to relevant studies were also searched. We applied
no restriction on language.
Selection criteria
We planned to included randomized controlled trials (RCTs) and quas-randomized trials comparing HFNC therapy with other forms
of non-invasive respiratory support for children. Non-invasive support encompassed cot, hood or tent oxygen; low-flow nasal cannulae
(flow rates ≤ 2 L/min); and continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) delivered via facial
or nasal mask/cannula. Treatment failure was defined by the need for additional respiratory support. We excluded children with a
diagnosis of bronchiolitis.
1High-flow nasal cannula therapy for respiratory support in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two review authors independently assessed all studies for selection and data extraction. We used standard methodological procedures
expected by The Cochrane Collaboration.
Main results
Our search yielded 922 records. A total of 109 relevant records were retrieved with reference to our search criteria. After duplicates
and irrelevant studies were removed, 69 studies were further scrutinized. Of these, 11 studies involved children. No study matched our
inclusion criteria.
Authors’ conclusions
Based on the results of this review, no evidence is available to allow determination of the safety or effectiveness of HFNC as a form of
respiratory support in children.
P L A I N L A N G U A G E S U M M A R Y
High-flow nasal cannula therapy for support of breathing in children
We reviewed evidence on the effectiveness of high-flow nasal cannula (HFNC) therapy in supporting children’s breathing. We found
11 studies in children.
Background
HFNC therapy delivers a mixture of air and oxygen via tubing that sits just inside the nostrils. For children hospitalized with breathing
difficulties caused by conditions such as pneumonia or trauma or after surgery, HFNC therapy may help to support their breathing.
This may reduce the need for other forms of breathing support such as life support. HFNC therapy can be used within the hospital
ward setting, the emergency department or the intensive care unit. This Cochrane review is important because it assesses available
evidence on the safety and effectiveness of HFNC compared with other forms of respiratory support, to help inform clinicians caring
for children with breathing difficulties.
Search date
We searched medical databases from the 1950s until April 2013.
Study characteristics
We included studies on children from four weeks to 16 years of age. We searched for randomized controlled trials; however we excluded
studies involving infants with bronchiolitis (a respiratory illness affecting infants that typically mimics a common cold) because children
with this condition are included in another Cochrane review.
Results
We found 11 studies involving children; however none matched our criteria.
Conclusion
It is important that good-quality studies are completed to identify indications as to the use and effectiveness of HFNC therapy in
supporting the breathing of ill children.
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B A C K G R O U N D
Description of the condition
Respiratory support is central to the care of critically ill children.
Support may be needed because of underlying disease processes
such as respiratory infection or pneumonia, neuromuscular dis-
orders, cardiac conditions or cardiac failure, and as the result of
other mechanisms such as upper airway obstruction, trauma and
injury or postsurgical interventions. Respiratory support can be
delivered non-invasively in the form of oxygen therapy, continu-
ous positive airway pressure (CPAP) or bilevel positive airway pres-
sure (BiPAP), or invasively via mechanical ventilation. Children
with significant respiratory distress and hypoxaemia often require
the latter. This may result in various forms of trauma to the lungs
and airways, collectively known as ventilator-induced lung injury
(VILI) (Dahlem 2003; The ARDS Network 2000).
Although VILI is the major concern with intubation and mechan-
ical ventilation, other effects on the body need to be considered.
Increased use of sedative drugs may lead to neuropathy or my-
opathy, which can increase recovery time. In turn, cardiovascular
support in the form of drug infusions may be needed to main-
tain blood pressure. These requirements increase the costs of care
provided to the child. Non-invasive methods of ventilation are an
ideal method of providing respiratory support without the need
for intubation and may avoid some of the additional harms asso-
ciated with positive-pressure ventilation, such as ventilator-asso-
ciated pneumonia (VAP) (Glossop 2012).
Non-invasive ventilation can be as simple as oxygen therapy deliv-
ered via face mask, nasal cannula or head box or devices delivering
CPAP/BiPAP via face mask or nasopharyngeal tubes, with pres-
sure generated by a dedicated driver or water column (i.e. bubble
CPAP) (Frey 2001; Frey 2003; Klein 1986). Devices delivering
CPAP/BiPAP can reduce the work of breathing and improve func-
tional residual capacity, potentially avoiding intubation, reducing
VILI and VAP and preventing other possible causes of harm (Reid
1984; Thorsteinsson 2002).
Disadvantages of thismethod of delivery are that it is cumbersome,
and themasks and tubes are poorly tolerated by young children and
infants (McGinley 2009; Spentzas 2009; Yong 2005). Obtaining
an adequate seal around the face of small children can be difficult,
thereby making delivery of CPAP/BiPAP variable and resulting in
ineffective ventilation. This is often due to the limited choice of
face masks developed for children with a wide range of ages and
stages of facial development. The need for a system that can deliver
CPAP while being comfortable and well tolerated by children is
an important consideration in providing non-invasive respiratory
support.
Description of the intervention
High-flow nasal cannula (HFNC) therapy has recently been in-
troduced for a range of patients from preterm infants to adults,
addressing the need for a simple, effective method of providing
respiratory support (Campbell 2006;McGinley 2009;McKiernan
2010; Shoemaker 2007). It offers an advantage over simple oxy-
gen therapy in that the gas mixture can be heated and humidified,
thereby reducing damage to upper airway mucosa, and the con-
centration of inspired oxygen can be titrated as required. This can
prevent inflammatory reactions and the naso-pulmonary bron-
choconstrictor reflex triggered by cold, dry air (Spentzas 2009).
The mixed gas is delivered via a nasal cannula that sits just inside
the nares. The flow rate delivered varies depending on the type of
cannula used but can range from 4 to 70 L/min.
How the intervention might work
It has been shown that delivery of nasal air at high flow rates may
cause incidental delivery of CPAP (Dysart 2009; Spence 2007;
Wilkinson 2008). The effects of this are yet to be fully understood.
It may be that the high flow flushes the dead space of the nasopha-
ryngeal cavity, resulting in alveolar ventilation as a greater fraction
of minute ventilation. It may also assist in the washout of carbon
dioxide, which may then reduce apnoea secondary to hypercapnia
and improve ventilation (Dysart 2009). High flow rates may also
provide some amount of positive pressure and thereby overcome
upper airway obstruction, again improving ventilation (McGinley
2009).
The amount of CPAP generated depends on the flow delivered
relative to the size of the patient, the size of the nasal cannula
used and the potential for leak around the nasal cannula (Kubicka
2008; Lampland 2009; Sreenan 2001). Three retrospective studies
in paediatric populations assessing HFNC therapy have demon-
strated that overall, ventilator days were significantly decreased af-
ter introduction of this therapy when compared with retrospec-
tive historical control groups (McKiernan 2010; Schibler 2011;
Shoemaker 2007).
HFNC therapy has also been reported to be better tolerated by the
patient than other forms of non-invasive ventilation (Roca 2010).
This can reduce the need for the sedation required to help patients
tolerate more invasive or uncomfortable forms of respiratory sup-
port.
Why it is important to do this review
HFNC therapy is an emerging treatment option for the respira-
tory support of children, especially in the intensive care unit. To
date, most findings have been derived from neonatal and adult
studies, with little clinical experience reported in the paediatric
population (McKiernan 2010). Clinical experience in the paedi-
atric population is reported in case reports and observational stud-
ies; few randomized controlled trials are reported (Mayfield 2013;
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McGinley 2009; Spentzas 2009). The Cochrane review of HFNC
therapy from the Cochrane Neonatal Group found only four el-
igible, randomized controlled trials and concluded that evidence
was insufficient to determine effectiveness, and more research was
needed (Wilkinson 2011). Two further reviews of HFNC therapy
are under way: in the adult population (Corley 2012) and in in-
fants with bronchiolitis (Beggs 2012). This review differs in that
it includes studies of children with a broader age range and more
diverse pathophysiologies such as type 1 and 2 respiratory failure,
parenchymal lung disease, neuromuscular disorders, respiratory
drive disorders and airway obstruction.
HFNC therapy has the potential to improve outcomes such as
reduced intubation and invasive ventilation (McKiernan 2010;
Schibler 2011; Wing 2012) in critically ill children. It is readily
applied and is not resource or cost intensive. Staff can easily be
trained in the application of HFNC therapy and in the care of
children using this therapy. It may also reduce the length of intu-
bation, asHFNC holds potential to transition between extubation
and low-flow nasal cannula oxygen delivery. An additional advan-
tage is that children requiring this therapymay be cared for outside
of the paediatric intensive care unit (PICU). However potential
risks are associated with its use, such as air leak syndrome, which
has been described in a case report (Hedge 2013), and other risks
extrapolated from the neonatal population, such as nasal trauma
and abdominal overdistention (Kopelman 2003). These potential
risks and benefits need to be assessed in the paediatric population.
O B J E C T I V E S
To determine whether HFNC therapy is more effective than other
forms of non-invasive therapy in paediatric patients who require
respiratory support.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included prospective randomized controlled trials (RCTs) and
quasi-randomized studies.
Types of participants
We included paediatric participants from four weeks corrected age
to 16 years of age requiring respiratory support for type 1 and
2 respiratory failure, parenchymal lung disease, neuromuscular
disorders, respiratory drive and airway obstruction. We excluded
a study in children with bronchiolitis.
Types of interventions
What constitutes ’high flow’ has not been well described in the
literature, nor has it been universally determined. Most paediatric
studies have been limited to using devices that deliver flow rates
in infants from 4 to 8 L/min (Arora 2012; Schibler 2011). Older
childrenmay have up to 30L/min delivered (McGinley 2009). For
the purposes of this review, high-flow nasal oxygen was defined as
the delivery of heated, humidified oxygen or blended oxygen with
air via nasal cannula at flow rates greater than 2 L/min. HFNC
therapy was compared with other means of non-invasive respi-
ratory support, such as cot, hood or tent oxygen; low-flow nasal
cannula (flow rates ≤ 2 L/min); and continuous positive airway
pressure (CPAP) or bilevel positive airway pressure (BiPAP).
Types of outcome measures
Primary outcomes
1. Hospital mortality.
2. Intubation rate.
3. Treatment failure (defined as the need for additional
respiratory support).
Secondary outcomes
1. Duration of any form of respiratory support in hours
(mechanical ventilation, non-invasive ventilation, high-flow
nasal cannula).
2. Length of stay in hospital in days.
3. Clinical severity score.
4. Length of paediatric intensive care unit (PICU) stay in days.
5. Complications.
◦ Air leaks (pneumothorax, pneumomediastinum,
pneumopericardium or pulmonary interstitial emphysema
(PIE)) reported individually or as a composite outcome.
◦ Nasal trauma (defined as erythema or erosion of the
nasal mucosa, nares or septum as assessed by a blinded observer).
◦ Barotrauma.
◦ Gastrointestinal distention.
Search methods for identification of studies
Electronic searches
We obtained all relevant studies irrespective of language or pub-
lication status (published, unpublished, in press and in progress)
using the following methods. We applied no limits in terms of
language or year of publication.
We searched Issue 4, 2013 of the Cochrane Central Register of
Controlled Trials (CENTRAL, see Appendix 1); MEDLINE via
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Ovid SP (January 1966 to April 2013, see Appendix 2); EM-
BASE via Ovid SP (January 1980 to April 2013, see Appendix 3);
CINAHL via EBSCO Host (1982 to April 2013, see Appendix
4); and LILACS via the BIREME interface (1982 to April 2013,
see Appendix 5).
We also searched the electronic databases of higher-degree theses
for relevant unpublished trials: Index to Theses (1950 to date),
Australian Digital Theses Program (1997 to April 2013) and Pro-
quest Digital Dissertations (1980 to April 2013).
We then combined our MEDLINE search strategy with the
Cochrane highly sensitive search strategy for identifying RCTs,
as suggested in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We adopted the MEDLINE search
strategy for searching in all other databases.
For ongoing trials, we searched theMetaRegister ofControlledTri-
als (http://www.controlledtrials.com/) and the National Research
Register (http://clinicaltrials.gov/).
Searching other resources
We handsearched citations from included studies.
Data collection and analysis
We used standard methodological procedures expected by The
Cochrane Collaboration.
Selection of studies
We used the search strategy described to obtain titles and abstracts
of studies that may be relevant to the review. Two review authors
(SM and JJ-C) independently performed this screening. Studies
that were not applicable were discarded. We found no ongoing
studies that matched our search criteria.
Data extraction and management
We adapted the standardized Cochrane Anasthesia Review Group
(CARG) data extraction form (Appendix 6) to capture relevant
data specific to this review. We (SM and JJ-C) used this form
independently to extract and collect data from the relevant study.
No disagreements arose.
Assessment of risk of bias in included studies
No studies were eligible for assessment of risk of bias. However,
we planned to assess risk of bias using the following domains with
judgements of high, low or uncertain.
1. Selection bias: incorporating random sequence generation
and allocation concealment.
2. Performance bias: blinding of participants and personnel.
3. Detection bias: blinding of outcome assessment.
4. Attrition bias: incomplete outcome data.
5. Reporting bias: selective reporting.
6. Other bias: other sources of bias.
Measures of treatment effect
No studies were found that could be included in this review. Ex-
cluded studies were tabulated with the reasons for exclusion doc-
umented in the Characteristics of excluded studies.
We planned to manage dichotomous outcome data, such as mor-
tality, by using risk ratios (RRs) to determine effect and by display-
ing them in a table. For continuous data, we planned to collect
means and standard deviations and to display them in a table. If
different scales were used to measure continuous data, we would
have calculated the standardized mean difference. Outcomes from
comparable trials would have used 95% confidence intervals to
estimate treatment effect. We would use forest plots to graphically
compare treatment effect with risk ratio for dichotomous data and
with mean difference for continuous outcomes.
Unit of analysis issues
The unit of analysis was the individual child. We expected to find
parallel-group study designs and no cross-over studies. As none
of the studies included in this review were randomized at cluster
level, unit of analysis was not an issue.
Dealing with missing data
If eligible studies with missing data were found, we planned to
contact the corresponding author.
Assessment of heterogeneity
We planned to analyse heterogeneity using the Chi2 test on N-
1 degrees of freedom, with an alpha of 0.1 used for statistical
significance, along with the I2 statistic (Higgins 2011).
Assessment of reporting biases
We planned to assess publication bias or small-study effects by
preparing a funnel plot. We planned to test for funnel plot asym-
metry if more than 10 studies were included in the meta-analysis.
We planned to obtain published and unpublished studies as a way
of addressing reporting bias.
Data synthesis
We planned to review the summary tables of included trials to
identify clinical heterogeneity amongst trials. If two or more ran-
domized trials had been found with comparable populations un-
dergoing similar interventions, we would have conducted a meta-
analysis with a random-effects model using RevMan 5.2.
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Subgroup analysis and investigation of heterogeneity
No studies were found to permit subgroup analyses or exploration
of heterogeneity (Sutton 2008).
Sensitivity analysis
No studies were found to allow sensitivity analysis.
Summary of findings
We planned to use the principles of the GRADE system (Guyatt
2008) to assess the quality of the body of evidence associated with
the following specific outcomes in our review.
1. Mortality.
2. Intubation.
3. Failure of treatment or escalation to non-invasive
ventilation.
4. Length of PICU stay.
5. Length of time on any form of respiratory support.
6. Oxygenation and respiratory assessment tools.
However, no studies were identified for inclusion.
R E S U L T S
Description of studies
See Characteristics of excluded studies.
Results of the search
Our search yielded 922 records. After duplicates and irrelevant ref-
erences were removed, 69 were further scrutinized. Eleven studies
involved children. No study met our criteria (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
No studies met our inclusion criteria.
Excluded studies
Ten studies did not meet the criteria of being randomized or quasi-
randomized (Abboud 2012; Arora 2012; Hedge 2013; Hough
2011; McGinley 2009; McKiernan 2010; Milesi 2013; Schibler
2011; Spentzas 2009; Wing 2012). One randomized controlled
trial was excluded because it included infants with bronchiolitis
(Hilliard 2012).Details are listed in theCharacteristics of excluded
studies.
Risk of bias in included studies
N/A.
Allocation
N/A.
Blinding
N/A.
Incomplete outcome data
N/A.
Selective reporting
N/A.
Other potential sources of bias
N/A.
Effects of interventions
N/A.
D I S C U S S I O N
Summary of main results
We found no randomized controlled trials of HFNC therapy in
children older than four weeks of age requiring respiratory sup-
port for type 1 or 2 respiratory failure, parenchymal lung disease,
neuromuscular disorders, respiratory drive or airway obstruction.
Overall completeness and applicability of
evidence
N/A.
Quality of the evidence
N/A.
Potential biases in the review process
We believe that any bias in this review is of low probability. We
ensured that language would not be a bias by imposing no re-
strictions on such. We used a well-constructed search strategy to
minimize the chance of missing randomized controlled trials that
fulfilled our inclusion criteria.
Agreements and disagreements with other
studies or reviews
This review supports the conclusion of other studies and re-
views conducted to evaluateHFNC therapy (Lee 2013;Wilkinson
2011) in that evidence of robust quality is insufficient to permit
determination of the superiority of HFNC therapy over other es-
tablished forms of non-invasive ventilation for children withmod-
erate to severe respiratory compromise. Further studies are needed
to quantify this and to identify clinical indicators regarding its use.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the results of this review, no evidence can be found to
allowdeterminationof the safety or effectiveness ofHFNCtherapy
as a form of respiratory support in children.
Implications for research
It is acknowledged that while the number of retrospective, observa-
tional andphysiological studies surrounding the support ofHFNC
therapy for respiratory support in children is increasing, adequately
8High-flow nasal cannula therapy for respiratory support in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
powered randomized controlled trials are needed. HFNC therapy
must be compared with CPAP and other forms of non-invasive
respiratory support. Clinically important outcomes, such as esca-
lation to CPAP or intubation, length of stay and duration of treat-
ment, need to be assessed. With such a broad range of ages and
disease processes in children, an aim of further research should be
to establish which subgroups benefit from HFNC therapy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abboud 2012 Retrospective chart review of all patients admitted to intensive care with a diagnosis of viral bronchiolitis from
2006 to 2010. 113 patients met inclusion criteria of < 12 months, initiation of HFNC on admission
Arora 2012 Prospective observational study to measure nasopharyngeal effects of HFNC in infants with bronchiolitis. 25
infants enrolled
Hedge 2013 Case series of three patients with air leak syndrome who were also treated with HFNC
Hilliard 2012 Prospective randomized controlled trial comparing HFNC versus head box oxygen therapy. 19 participants
enrolled, all with viral bronchiolitis
Hough 2011 Prospective physiological study comparing HFNC at different flow rates. 13 participants enrolled, all with
bronchiolitis
McGinley 2009 Prospective observational study of 12 participants with obstructive apnoea-hypopnoea syndrome treated with
nasal insufflation at 20 L/min
McKiernan 2010 Retrospective chart review comparing intubation rates of infants with bronchiolitis admitted before and in the
season after HFNC was implemented. 115 participants included in the review
Milesi 2013 Prospective physiological study of 21 infants < six months with viral bronchiolitis and HFNC therapy. Pharygneal
and oesophageal pressures measured at different flow rates
Schibler 2011 Retrospective chart review of infants < 24 months admitted to PICU between January 2005 and December 2009,
requiring HFNC therapy. 298 infants included in the review
Spentzas 2009 Observational study of all participants (newborn to 12 years) requiring HFNC, admitted between January 2005
and January 2007 to PICU. 46 participants included in the study
Wing 2012 Retrospective chart review of all patients admitted from ED to PICU with acute respiratory insufficiency from
January 2006 to December 2009. Patients admitted before HFNC availability were compared with patients
admitted after HFNC became available (two cohorts, before and after implementation of clinical guidelines).
848 participants included in the review
12High-flow nasal cannula therapy for respiratory support in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Oxygen Inhalation Therapy explode all trees
#2 intubation rates*
#3 (#1 AND #2)
#4 ((high flow (nasal or prong or cannula)) or (nasal near oxygen)):ti,ab
#5 (#3 OR #4)
Search from Issue 4 2013.
Appendix 2. MEDLINE (Ovid SP) search strategy
1. (exp Oxygen Inhalation Therapy/ and intubation rates*.af.) or (high flow adj3 (nasal or prong or cannula)).mp. or (nasal adj3
oxygen).mp.
2. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or
trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.
3. 1 and 2
Search from January 1966- April 2013.
Appendix 3. EMBASE (Ovid SP) search strategy
1. (exp oxygen therapy/ and intubation rates*.af.) or (high flow adj3 (nasal or prong or cannula)).mp. or (nasal adj3 oxygen).mp.
2. (randomized-controlled-trial/ or randomization/ or controlled-study/ or multicenter-study/ or phase-3-clinical-trial/ or phase-4-
clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* ormulticenter* or factorial* or placebo*
or volunteer*).mp. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab. or (latin adj square).mp.) not (animals not
(humans and animals)).sh.
3. 1 and 2
Search from January 1980 to April 2013.
Appendix 4. CINAHL (EBSCO host) search strategy
S1 (((MH “Oxygen Therapy”) and intubation rates*)) OR ((high flow and (nasal or prong or cannula))) OR (nasal and oxygen)
S2 (MM “Randomized Controlled Trials”) OR (MM “Random Assignment”) OR (MH “Clinical Trials+”) OR (MM “Multicenter
Studies”) OR (MM “Prospective Studies”) OR (MM “Placebos”) OR (MM “Double-Blind Studies”) OR (MM “Triple-Blind Studies”)
OR (MM “Single-Blind Studies”)
S3 S1 and S2
Seach from 1982-April 2013.
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Appendix 5. LILACS search strategy
(oxygen therapy and intubation rates$) or (high flow and (nasal or prong or cannula)) or (nasal and oxygen) [Palabras]
Search from 1982 to April 2013.
Appendix 6. Data extraction form
Review title or ID
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
Notes:
1. General information
Date form completed (dd/mm/yyyy)
Name/ID of person extracting data
Report title
(title of paper/abstract/report from which data are extracted)
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(Continued)
Report ID
(ID for this paper/abstract/report)
Reference details
Report author contact details
Publication type
(e.g. full report, abstract, letter)
Study funding sources
(including role of funders)
Possible conflicts of interest
(for study authors)
Notes:
2. Study eligibility
Study
characteristics
Eligibility criteria
(insert eligibility criteria for each
characteristic as defined in the pro-
tocol)
Yes No Unclear Location in text
(pg & ¶/fig/table)
Type of study Randomized controlled trial
Controlled clinical trial
(quasi-randomized trial)
Participants Paediatric patients from four
weeks corrected to 16 years of
age
Types of inter-
ventions High-flow nasal oxygen (heated/
humidified, flow > 2 L/kg/min)
Comparator: non-invasive respi-
ratory support such as cot/tent/
hood, low-flow oxygen or CPAP
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(Continued)
Types of out-
come measures
Hospital mortality; intubation
rate; treatment failure
Secondary: duration of any form
of respiratory support; length
of hospital stay; clinical severity
score; length of PICU stay; com-
plications-air leak, nasal trauma,
nosocomial sepsis, barotrauma,
gastrointestinal distention
INCLUDE EXCLUDE
Reason for ex-
clusion
Notes:
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW.
3. Methods
Descriptions as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Aim of study
Design (e.g. parallel, cross-over,
cluster)
Unit of allocation
(by individuals, cluster/groups or
body parts)
Start date
End date
Total study duration
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(Continued)
Ethical approval needed/ob-
tained for study Yes No Unclear
Notes:
4. Risk of bias assessment
See Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Domain Risk of bias Support for judgement Location in text
(pg & ¶/fig/table)
Low risk High risk Unclear
Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
Blinding of partic-
ipants and person-
nel
(performance bias)
Outcome group: all/
(if required) Outcome group:
Blinding of out-
come assessment
(detection bias)
Outcome group: all/
(if required) Outcome group:
Incomplete
outcome data
(attrition bias)
Selective outcome
reporting?
(reporting bias)
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(Continued)
Other bias
Notes:
5. Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Total no. randomly assigned
(or total population at start of study for
NRCTs)
Clusters
(if applicable, no., type, no. people per cluster)
Withdrawals and exclusions
(if not provided below by outcome)
Age
Sex
Severity of illness
Co-morbidities
Other treatment received (additional to
study intervention)
Subgroups measured
Subgroups reported
Notes:
6. Intervention groups
Copy and paste table for each intervention and comparison group.
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Intervention group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name HFNC
No. randomly assigned to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Invasive ventilation
No. randomly assigned to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
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(Continued)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison group 2
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Noninvasive ventilation
No. randomly assigned to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
7. Outcomes
Copy and paste table for each outcome.
Outcome 1
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Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Hospital mortality
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 2
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Intubation rate
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(Continued)
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 3
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Treatment failure-escalation to
other form of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
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(Continued)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 4
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Duration of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 5
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Complications-air leak, nasal
trauma, nosocomial sepsis, baro-
trauma, gastrointestinal distention
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
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(Continued)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 6
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of hospital stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 7
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Clinical severity score
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
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(Continued)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 8: secondary outcome
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of PICU stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
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(Continued)
Notes:
8. Results
Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.
Dichotomous outcome
Outcome HFNC Invasive ventilation Non-invasive ventilation Details
No. with
event
No. without
event
No. with
event
No. without
event
No. with
event
No. without
event
Intubation
Failure of
treatment
Hospital mor-
tality
Complica-
tions
Continuous outcome
Out-
come
Unit of
mea-
sure-
ment
HFNC group Invasive ventilation
group
Non- invasive
group
Details
n M SD n M SD n M SD
Length
of PICU
stay
Clini-
cal sever-
ity score
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(Continued)
Dura-
tion of
respira-
tory sup-
port
LOS-
hospital
9. Applicability
Have important populations been ex-
cluded from the study? (consider disadvan-
taged populations and possible differences in
the intervention effect)
Yes No Unclear
Is the intervention likely to be aimed at
disadvantaged groups? (e.g. lower socioeco-
nomic groups)
Yes No Unclear
Does the study directly address the re-
view question?
(any issues of partial or indirect applicability)
Yes No Unclear
Notes:
10. Other information
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Key conclusions of study authors
References to other relevant studies
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(Continued)
Correspondence required for further
study information (from whom, what and
when)
Notes:
C O N T R I B U T I O N S O F A U T H O R S
Conceiving of the review: Sara Mayfield (SM).
Co-ordinating the review: SM.
Undertaking manual searches: SM.
Screening search results: SM and Jacqui Jauncey-Cooke (JJ-C).
Organizing retrieval of papers: SM.
Screening retrieved papers against inclusion criteria: SM and JJ-C.
Appraising quality of papers: SM, JJ-C and Judith L Hough (JH).
Abstracting data from papers: SM and JJ-C.
Writing to authors of papers for additional information: SM.
Providing additional data about papers: SM.
Obtaining and screening data on unpublished studies: SM.
Managing data for the review: SM, JJ-C and Fiona Bogossian (FB).
Entering data into Review Manager (RevMan 5.2): SM.
Interpreting data: SM, JJ-C, FB, JH and Andreas Schibler (AS).
Making statistical inferences: SM, JJ-C, FB and Kristen Gibbons (KG).
Writing the review: SM.
Serving as guarantor for the review (one author): FB.
Taking responsibility for reading and checking the review before submission: JJ-C, FB, AS and JH.
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D E C L A R A T I O N S O F I N T E R E S T
Sara Mayfield and Andreas Schibler have received financial and equipment support from Fisher Paykel Healthcare to conduct two
observational studies involving HFNC therapy. These studies would not be eligible for inclusion in this review.
Jacqueline Jauncey-Cooke: none known.
Judith L Hough: none known:
Kristen Gibbons: none known.
Fiona Bogossian: none known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Initially we planned to include all paediatric patients requiring HFNC therapy; however, because of the overlap with another Cochrane
Review of HFNC in infants with bronchiolitis (Beggs 2012), we excluded children with bronchiolitis from our review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Masks; Oxygen Inhalation Therapy [∗methods]; Respiration, Artificial [∗methods]
MeSH check words
Child; Humans
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